Schwarz Tino F, Horacek Thomas, Knuf Markus, Damman Hanns-Gerd, Roman François, Dramé Mamadou, Gillard Paul, Jilg Wolfgang
Stiftung Juliusspital, Körperschaft des öffentlichen Rechts, Juliuspromenade 19, 97070 Würzburg, Germany.
Vaccine. 2009 Oct 23;27(45):6284-90. doi: 10.1016/j.vaccine.2009.01.040.
Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adults aged 18-60 years who received a single booster administration of either A/Indonesia/05/2005 or A/Vietnam/1194/2004 vaccine 6 months after a 1- or 2-dose (given 21 days apart) primary vaccination with A/Vietnam/1194/2004. All prime-boost schedules assessed induced early (7 days post-booster) humoral responses that met regulatory acceptance criteria. Two doses of A/Vietnam/1194/2004 given 6 months apart achieved equivalent homologous seroprotection after the second vaccination (89.6%), when compared to two doses given 21 days apart (92.7-93.2%). Remarkably, two doses of A/Vietnam/1194/2004 given 6 months apart induced a higher cross-reactive seroprotection against A/Indonesia/05/2005 (83.3%) when compared to two doses given 21 days apart (41.5-54.5%). A 6-month A/Indonesia/05/2005 booster dose after one primary dose of A/Vietnam/1194/2004 vaccine induced 92.5% seroprotection against A/Indonesia/05/2005 and 98.1% against A/Vietnam/1194/2004. Since a single booster 6 months after one primary dose of AS03-adjuvanted vaccine induces strong and rapid seroprotective immune response against both homologous and heterologous H5N1 strains, these results might have important implications for public health strategy aiming to organize vaccination campaigns with pre-pandemic vaccines.
人们正在考虑用大流行前的疫苗对人群进行预免疫,以便在随后接种与致病性大流行毒株更匹配的真正大流行疫苗时,使免疫反应最大化。本研究通过评估不同的初始免疫方案来探索这种初免 - 加强免疫概念,初始免疫采用含有3.75微克血凝素(HA)的大流行前A/越南/1194/2004(NIBRG - 14)疫苗,随后在6个月后用含有3.75微克HA的同一毒株疫苗或来自不同分支的异源毒株A/印度尼西亚/05/2005(IBCDC - RG2)疫苗进行加强免疫。在这项多中心、开放、随机研究(NCT00430521)中,我们测量了四组(每组N = 48 - 60)18 - 60岁成年人的免疫反应,这些成年人在接受1剂或2剂(间隔21天)A/越南/1194/2004初次免疫6个月后,接受了一剂A/印度尼西亚/05/2005或A/越南/1194/2004疫苗的加强免疫。所有评估的初免 - 加强免疫方案均诱导出了符合监管验收标准的早期(加强免疫后7天)体液免疫反应。与间隔21天接种两剂(92.7% - 93.2%)相比,间隔6个月接种两剂A/越南/1194/2004在第二次接种后产生了相当的同源血清保护率(89.6%)。值得注意的是,与间隔21天接种两剂(41.5% - 54.5%)相比,间隔6个月接种两剂A/越南/1194/2004诱导出了更高的针对A/印度尼西亚/05/2005的交叉反应血清保护率(83.3%)。在一剂A/越南/1194/2004疫苗初次免疫后6个月接种一剂A/印度尼西亚/05/2005加强疫苗,诱导出了92.5%的针对A/印度尼西亚/05/2005的血清保护率和98.1%的针对A/越南/1194/2004的血清保护率。由于在一剂AS03佐剂疫苗初次免疫6个月后进行单次加强免疫可诱导出针对同源和异源H5N1毒株的强烈且快速的血清保护性免疫反应,这些结果可能对旨在组织大流行前疫苗接种活动的公共卫生策略具有重要意义。